Literature DB >> 9049414

Analysis of vif-defective human immunodeficiency virus type 1 (HIV-1) virions synthesized in 'non-permissive' T lymphoid cells stably infected with selectable HIV-1.

C Ochsenbauer1, T Wilk, V Bosch.   

Abstract

In order to facilitate analyses of the molecular function of the human immunodeficiency virus type 1 (HIV-1) Vif protein, we have developed a cell culture model-system which allows permanent production of genotypically and phenotypically vif-defective HIV-1 virions in 'non-permissive' H9 cells. Using recombinant, replication-competent HIV-1 proviruses coding for a selectable marker gene (gpt) instead of nef, two stably infected H9 subclones named M2 (vif-mutant) and WX (wild-type), respectively, were generated. Virions released from cell line M2--displaying the expected vif-defective phenotype--are produced permanently, and in an at least 50 times higher amount than virus particles from acutely vif-negative HIV-1-infected H9 cells. Analysis of viral protein composition and the electron-microscopic morphology of vif-mutant virions did not reveal any detectable differences in comparison to wild-type virions.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9049414     DOI: 10.1099/0022-1317-78-3-627

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  17 in total

1.  The Vif and Gag proteins of human immunodeficiency virus type 1 colocalize in infected human T cells.

Authors:  J H Simon; R A Fouchier; T E Southerling; C B Guerra; C K Grant; M H Malim
Journal:  J Virol       Date:  1997-07       Impact factor: 5.103

2.  The regulation of primate immunodeficiency virus infectivity by Vif is cell species restricted: a role for Vif in determining virus host range and cross-species transmission.

Authors:  J H Simon; D L Miller; R A Fouchier; M A Soares; K W Peden; M H Malim
Journal:  EMBO J       Date:  1998-08-10       Impact factor: 11.598

3.  Human immunodeficiency virus type 1 Vif protein is packaged into the nucleoprotein complex through an interaction with viral genomic RNA.

Authors:  M A Khan; C Aberham; S Kao; H Akari; R Gorelick; S Bour; K Strebel
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

4.  Association of human immunodeficiency virus type 1 Vif with RNA and its role in reverse transcription.

Authors:  M Dettenhofer; S Cen; B A Carlson; L Kleiman; X F Yu
Journal:  J Virol       Date:  2000-10       Impact factor: 5.103

5.  Cellular and viral specificities of human immunodeficiency virus type 1 vif protein.

Authors:  N Madani; D Kabat
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

6.  The human immunodeficiency virus type 1 Vif protein reduces intracellular expression and inhibits packaging of APOBEC3G (CEM15), a cellular inhibitor of virus infectivity.

Authors:  Sandra Kao; Mohammad A Khan; Eri Miyagi; Ron Plishka; Alicia Buckler-White; Klaus Strebel
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

7.  Highly purified human immunodeficiency virus type 1 reveals a virtual absence of Vif in virions.

Authors:  M Dettenhofer; X F Yu
Journal:  J Virol       Date:  1999-02       Impact factor: 5.103

8.  Implication of the lymphocyte-specific nuclear body protein Sp140 in an innate response to human immunodeficiency virus type 1.

Authors:  Navid Madani; Robert Millette; Emily J Platt; Mariana Marin; Susan L Kozak; Donald B Bloch; David Kabat
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

9.  Influence of primate lentiviral Vif and proteasome inhibitors on human immunodeficiency virus type 1 virion packaging of APOBEC3G.

Authors:  Bindong Liu; Xianghui Yu; Kun Luo; Yunkai Yu; Xiao-Fang Yu
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

10.  Mutational analysis of the HIV-1 auxiliary protein Vif identifies independent domains important for the physical and functional interaction with HIV-1 reverse transcriptase.

Authors:  Alexandra Kataropoulou; Chiara Bovolenta; Amalia Belfiore; Sonia Trabatti; Anna Garbelli; Simona Porcellini; Rossella Lupo; Giovanni Maga
Journal:  Nucleic Acids Res       Date:  2009-04-15       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.